Research progress in effect of pelvic bone marrow-sparing intensity-modulated radiotherapy on hematologic toxicity in pelvic tumor patients after concurrent chemoradiotherapy

Abstract

Concurrent chemoradiotherapy can improve the survival rate in patients with advanced pelvic tumors. However, it also increases the incidence of hematologic toxicity and other adverse events. Patients cannot tolerate these adverse events and discontinue the therapy. Pelvic bone marrow-sparing intensity-modulated radiotherapy (PBMS-IMRT) possesses obvious advantages in reducing the radiation dose and volume of the pelvic bone marrow. In this article, comparison between PBMS-IMRT and other irradiation therapies, correlation between dosimetric parameters and hematologic toxicity and imaging methods with precise delineation of the active bone marrow were reviewed. Key words: Pelvic neoplasm/pelvic bone marrow-sparing intensity-modulated radiotherapy; Hematologic toxicity; Dosimetric parameters